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Abstract
Background Chronic pain and depression often co-occur,
and pain may exacerbate depression in people with
dementia.
Objective The objective of this study was to assess the
efficacy and safety of analgesic treatment for depression in
nursing home patients with advanced dementia and clini-
cally significant depressive symptoms.
Methods We conducted a multicentre, parallel-group,
double-blind, placebo-controlled trial in 47 nursing homes,
including 162 nursing home patients aged C 60 years with
dementia (Mini-Mental State Examination B 20) and
depression (Cornell Scale for Depression in Demen-
tia C 8). Patients were randomised to receive active anal-
gesic treatment (paracetamol or buprenorphine transdermal
system) or identical placebo for 13 weeks. The main out-
come measure was the change in depression (Cornell Scale
for Depression in Dementia) from baseline to 13 weeks,
assessed using linear mixed models with fixed effects for
time, intervention and their interaction in the models.
Secondary outcomes were to assess whether any change in
depression was secondary to change in pain (Mobilisation-
Observation-Behaviour-Intensity-Dementia-2 Pain Scale)
and adverse events.
Results The mean depression change was - 0.66 (95%
confidence interval - 2.27 to 0.94) in the active group
(n = 80) and - 3.30 (- 4.68 to -1.92) in the placebo group
(n = 82). The estimated treatment effect was 2.64
(0.55–4.72, p = 0.013), indicating that analgesic treatment
had no effect on depressive symptoms from baseline to
13 weeks while placebo appeared to ameliorate depressive
symptoms. There was no significant reduction in pain in the
active treatment group (paracetamol and buprenorphine
combined) vs. placebo; however, a subgroup analysis
demonstrated a significant reduction in pain for paraceta-
mol vs. placebo [by - 1.11 (- 2.16 to - 0.06, p = 0.037)]
from week 6 to 13 without a change in depression.
Buprenorphine did not have significant effects on depres-
sion [3.04 (- 0.11 to 6.19), p = 0.059] or pain [0.47
(- 0.77 to 1.71), p = 0.456] from 0 to 13 weeks. Thirty-
five patients were withdrawn from the study because of
adverse reactions, deterioration or death: 25 (31.3%) dur-
ing active treatment [23 (52.3%) who received buprenor-
phine], and ten (12.2%) in the placebo group. The most
frequently occurring adverse events were psychiatric
(17 adverse reactions) and neurological (14 adverse
reactions).
Conclusion Analgesic treatment did not reduce depression
while placebo appeared to improve depressive symptoms
significantly by comparison, possibly owing to the adverse
effects of active buprenorphine. The risk of adverse events
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warrants caution when prescribing buprenorphine for
people with advanced dementia.
Trial registration ClinicalTrials.gov NCT02267057 (reg-
istered 7 July, 2014) and Norwegian Medicines Agency
EudraCT 2013-002226-23.
Key Points
Contrary to our hypothesis, patients who received
active analgesic treatment had more persistent
depressive symptoms
The buprenorphine transdermal system may
exacerbate neuropsychiatric symptoms in dementia
and should be used with caution in this group
1 Introduction
Approximately 40% of nursing home patients receive
antidepressants [1], and over 80% have dementia [2].
Although some studies suggest that antidepressants may be
beneficial for depression in people with dementia [3, 4],
several later studies have found negative results [5, 6]. The
most commonly prescribed antidepressants are selective
serotonin reuptake inhibitors such as sertraline, and nora-
drenergic and specific serotonergic antidepressants such as
mirtazapine [7]. Lyketsos et al. found that sertraline
reduced depression in Alzheimer’s disease compared with
placebo (n = 44) [4], this result was followed by a larger
study from the same group which found no benefit of
sertraline compared with placebo (n = 131) [6]. Banerjee
et al. found that sertraline or mirtazapine did not reduce
depression in dementia, and that participants who received
active treatment had significantly higher rates of adverse
events such as nausea and sedation compared with placebo
(n = 326) [5]. Updated systematic reviews and meta-anal-
yses conclude that the current evidence base for antide-
pressants in dementia is equivocal [8, 9].
More than 60% of nursing home patients experience
pain, often of moderate-to-severe intensity [10, 11]. Failure
to systematically assess and treat pain leads to the risk of
chronic pain, particularly in people with dementia who
gradually lose their ability to reliably describe symptom
severity [12]. Pain has been identified as a possible con-
tributing factor to depression in nursing homes, even in
patients with advanced dementia [13, 14]. Pain and
depression share a complex relationship, known as the
pain-depression dyad, implying that the conditions
commonly coexist, exacerbate each other, share common
signal pathways and neurotransmitters, and respond to
similar treatments [15]. A previous cluster randomised trial
suggests that a 12-week stepwise protocol for treating pain
with paracetamol, buprenorphine transdermal system
(TDS), morphine or pregabalin may reduce depressive
symptoms in people with advanced dementia and agitation
[16]. However, depression was not an inclusion criterion in
this study, and the pain intervention was not placebo
controlled.
Buprenorphine is currently recommended for opioid
analgesia in the elderly [17]. As a partial agonist/antago-
nist, it provides effective analgesia with a low potential for
serious adverse effects including respiratory depression
[17]. Because it undergoes hepatic metabolism and excre-
tion, it does not require dose adjustment in renal insuffi-
ciency [17]. Some evidence suggests that buprenorphine
may also have a potential for mood-elevating effects in
depression [18]. Paracetamol is the most widely used non-
opioid analgesic in the elderly, and may also exert an effect
in the central processing and response to emotional stimuli
[19].
Therefore, we wished to examine whether a stepwise
protocol for treating pain using paracetamol or buprenor-
phine ameliorated depressive symptoms in nursing home
patients with moderate-to-severe dementia and clinically
significant depressive symptoms, controlling for the choice
of analgesic, the presence of moderate-to-severe pain and
dementia severity. To assess whether any change in
depressive symptoms was secondary to an analgesic effect,
we also examined whether the intervention effectively
reduced pain compared with placebo.
2 Materials and Methods
2.1 Study Design
This was a 13-week, multicentre, parallel-group, double-
blind, randomised placebo-controlled trial conducted in
long-term and dementia wards in 47 nursing homes from
12 municipalities in Norway (Bergen, Baerum, Fjell,
Kvam, Meland, Os, Oslo, Sandnes, Stavanger, Sula, Sund
and Aalesund). Depending on ongoing medical treatment
and clinical investigation, participants were prescribed
either paracetamol tablets (maximum 3 g/day) or
buprenorphine TDS (maximum 10 lg/hour), and were
randomised to receive either active treatment or placebo.
2.2 Participants
We screened 2323 nursing home patients for inclusion
from 18 August, 2014 to 13 September, 2016. Data
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collection was completed by 20 December, 2016. Eligible
participants were elderly (C 60 years) long-term patients
(i.e. residents with permanent placement) who had been
living in the participating ward for at least 4 weeks prior to
screening, with dementia according to the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition cri-
teria for major neurocognitive disorders, Mini-Mental State
Examination (MMSE) score B 20 [20] and clinically sig-
nificant depression [Cornell Scale for Depression in
Dementia (CSDD) score C 8 at screening] of at least
4 weeks’ duration [21]. Exclusion criteria were: cognitive
impairment related to other diagnoses than Alzheimer’s
disease; frontotemporal dementia; vascular dementia;
dementia with Lewy bodies or mixed dementia (e.g. trau-
matic head injury, chronic alcohol abuse or Huntington’s
disease; assessed by a review of medical records); life
expectancy\ 6 months; severe pain [Mobilisation-Obser-
vation-Behaviour-Intensity-Dementia-2 (MOBID-2) Pain
Scale score C 8] [22]; severe aggression (with Neuropsy-
chiatric Inventory—Nursing Home version aggression
item C 8) [23]; suicide risk; severe hepatic or renal
insufficiency; anaemia (haemoglobin\ 8.5 mmol/L in
men,\ 7.5 mmol/L in women); severe disease or injury
that could interfere with study participation; comatose
state; participation in another experimental trial; having no
carer who was familiar with the patient; diagnosis of psy-
chosis or other severe mental disorder prior to dementia
diagnosis (e.g. schizophrenia, schizoaffective disorder and
bipolar disorder); severe psychiatric or neurological dis-
order; uncontrolled epilepsy; the clinician responsible for
care or study clinician considered that the patient had any
physical condition that would make participation in the
trial distressing or likely to increase patient discomfort;
contraindication, known allergy, adverse reaction or clini-
cally significant drug interaction to the assigned study
treatment; and scheduled prescriptions for any opioid
analgesic other than or exceeding buprenorphine 5 lg/
hour. When a patient at any point fulfilled any one exclu-
sion criterion, we conducted no further assessments and the
reason for exclusion was recorded.
At baseline, after a minimum of 4 weeks, we re-assessed
the eligible patients for depression. To avoid false nega-
tives at this point, we excluded patients who scored below
the cut-off for greatest sensitivity on the CSDD scale
(CSDD score C 6). The screening cut-off value of C 8 and
the re-assessment threshold for persistent depression of
C 6 on the CSDD scale correspond to the optimal cut-off
points for specificity and sensitivity, respectively, as sum-
marised in a recent meta-analysis [24].
2.3 Randomisation and Masking
The trial was double blinded, and participants were ran-
domly allocated to each arm in a 1:1 ratio according to
computer-generated random numbers in blocks of ten
(paracetamol) and 12 (buprenorphine) with no stratification
factors. Statisticians generated and sent the randomisation
lists directly to the production and packing facilities
without researcher involvement. Paracetamol and identical
inert placebo tablets were purchased from Kragero
Tablettproduksjon A/S, Norway. Mundipharma Research
Limited, UK provided buprenorphine TDS and identical
inert placebo. The patients, carers, clinicians, pharmacy,
researchers and study statistician were masked to group
identity until completion of the protocol.
2.4 Intervention
As shown in Table 1, participants without current sched-
uled analgesics or who received B 1 g/day of paracetamol
were allocated to step 1, oral paracetamol (increased to a
maximum of 3 g/day, active or placebo). Participants who
were already prescribed regular doses of[ 1 g/day of
paracetamol, buprenorphine 5 lg/hour or non-steroidal
anti-inflammatory drugs (except low-dose acetylsalicylic
acid) were allocated to step 2, buprenorphine TDS (maxi-
mum dose of 10 lg/hour, active or placebo). Patients with
dysphagia, to whom it was not deemed feasible to
administer oral tablets, were allocated to step 2 regardless
of whether they were already using paracetamol.
We used a fixed-dose regimen throughout the 13-week
treatment period: paracetamol 1 g tablet/placebo was
administered at breakfast, lunch and dinner (approximately
8:00 a.m., noon, 6:00 p.m.) for a total daily dose of 3 g in
the active group (corresponding to step 1; see Table 1). If
the patient was using paracetamol B 1 g/day prior to study
inclusion, the study treatment was prescribed in addition to
the basis dose, giving a maximum total dose of 1 g three
times daily (supplement active or placebo) [step 1b;
Table 1]. Buprenorphine/placebo TDS was changed
weekly for a total dose of 5 lg/hour in the active group
(step 2a; Table 1). However, if the patient was using
buprenorphine TDS 5 lg/hour prior to study inclusion, the
study treatment was administered as an additional 5 lg/
hour TDS (active or placebo) to yield a total dose of 10 lg/
hour in the active group (step 2b; Table 1). Patients who
were unable to tolerate study treatment were withdrawn
from the study and treated as clinically appropriate.
2.5 Concomitant Drugs
All participants continued their usual medical treatment
after inclusion in the study (including any regular or ‘as
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needed’ analgesic). The use of ‘as needed’ analgesics was
allowed and monitored during the study, ensuring that all
patients received adequate pain treatment irrespective of
group allocation. Ongoing treatment with antidepressants,
other psychotropic drugs and regular analgesics was
allowed if the dose had remained stable for 4 weeks prior
to study inclusion. Clinicians were advised to keep doses of
psychotropic and analgesic drugs unchanged during the
study period if possible. If lasting changes were made to
regular analgesic treatment or antidepressants, the patient
was withdrawn from the study. Lists of regular and ‘as
needed’ prescriptions and documentation of administered
doses were extracted from medical records at each visit.
2.6 Primary and Secondary Outcome Measures
Depressive symptoms were assessed using the CSDD scale,
which has been validated and used in clinical studies
including people with and without dementia [24]. Each of
the 19 items is rated from zero (no symptoms) to two
(severe symptoms), and yields a sum score of between zero
(no depression) and 38 (most severe depression). While the
CSDD scale alone cannot be used to accurately diagnose
depression in dementia, it is useful as a screening tool and
sufficiently precise to assess change in depressive symptom
burden over time. Pain was assessed using the MOBID-2
Pain Scale, a two-part staff-administered behavioural
instrument to assess pain in older persons with advanced
dementia (see the Electronic Supplementary Material 1)
[22]. The evaluation of inferred pain intensity is based on
the patient’s pain behaviours during standardised guided
movements of different body parts (Part 1), and pain
behaviours that might be related to internal organs, head
and skin are recorded on an anatomical figure along with
inferred pain intensity for each region to allow monitoring
over time (Part 2). Excellent interrater and test-retest reli-
ability, internal consistency and validity have been repor-
ted [22]. The tool has also demonstrated responsiveness to
treatment, as it is able to detect change in the total score
(range 0–10) after pain treatment has been initiated [22].
For subgroup analyses, mild/no pain was defined as
MOBID-2\ 3 and moderate/severe pain as MOBID-
2 C 3. To assess cognitive function at inclusion, we used
the MMSE as a screening tool, with MMSE scores of 0–10
defined as severe and MMSE scores of 11–20 defined as
moderate dementia [25]. Although the MMSE scale poorly
distinguishes between patients with no/questionable
dementia, it has shown high agreement with the Clinical
Dementia Rating scale for the staging of moderate and
severe dementia using these cut-off scores [25]. Assess-
ments of depression (CSDD) and pain (MOBID-2) were
made at baseline and 6 and 13 weeks. Adverse events and
tolerability were monitored and recorded at each visit. The
primary outcome was the effect of analgesic treatment on
change in depressive symptoms (CSDD) from baseline to
13 weeks. Secondary outcomes were the effect of analgesic
treatment (paracetamol or buprenorphine) on change in
pain (MOBID-2) from baseline to 13 weeks, and adverse
events and dropout from treatment.
2.7 Sample Size
As a preliminary sample size estimate, we used results
from Banerjee et al., who found in their updated power
analyses that approximately 260 participants would be
required to provide 90% power to detect a 2-point differ-
ence in the CSDD scale (standard deviation 5; standardised
effect size 0.4) between two groups (active and placebo
treatment), allowing for 15% dropouts [5]. This estimate
was used as a preliminary goal, when inclusion and dropout
rates were unknown, and was reviewed when the first 113
patients had completed our 13-week trial protocol (or
dropped out). We calculated our revised sample size using
a sample size formula for longitudinal data because we
have data with repeated measurements. We used a sample
size formula for a longitudinal continuous response, where
the correlation between repeated measurements (intra-
cluster correlation) is taken into account, with the purpose
to estimate the intervention effect on average over the total
follow-up period [26]. This formula applies for group
Table 1 Study treatment steps 1–2
Step Regular analgesic treatment Study
treatment
Dose
1 No analgesics (1a) or paracetamol B 1 g/day (1b) Paracetamol
tablets
Maximum 3 g/day
Placebo tablets Inert placebo
2 Non-opioid analgesics (paracetamol[ 1 g/day, and/or NSAID), or no analgesics, but with




10 lg/h in 2b)
Placebo TDS Inert placebo
NSAID non-steroidal anti-inflammatory drug, except low-dose acetylsalicylic acid, TDS transdermal system
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comparisons with longitudinal data, such as randomised
controlled trials. The same parameters (standard deviation
5, standardised effect size 0.4, 90% power, p\ 0.05) were
used in the revised calculation, but based on available data
from the first 113 patients, we were able to estimate the
correlation coefficient of repeated measurements within
individuals (intra-cluster correlation) with greater precision
in the revised sample size calculation (intra-cluster corre-
lation 0.25). The final estimate required 66 patients in each
group to obtain 90% power to detect a 2-point CSDD
difference. Adjusting for 20% dropouts, our final aim was
to include 165 participants in total.
2.8 Statistical Analysis
Baseline characteristics were described as mean (standard
deviation) for continuous variables, and with the number of
patients and percentages of the sample size for categorical
variables. Differences in adverse outcomes (deaths)
between active treatment and placebo were assessed using
the Pearson v2 test for categorical variables. Treatment
effects on both the primary outcome (depression assessed
by the CSDD) and the secondary outcome (pain assessed
by the MOBID-2 Pain Scale) were assessed separately
using linear mixed-effects models, which incorporated all
assessments at baseline, 6 and 13 weeks. We treated time
as a categorical variable, and included fixed effects for
time, intervention and their interaction in the models. To
account for clustering, the models were fitted with random
intercepts for nursing home units and patients. Treatment
effects were calculated for active treatment vs. placebo,
these analyses were repeated with the use of other anal-
gesics or antidepressants at baseline as covariates to control
for any impact of concomitant drug use. We also conducted
pre-planned subgroup analyses for paracetamol tablets
compared with placebo tablets, buprenorphine TDS com-
pared with placebo TDS, and to investigate treatment
effects stratified for level of cognitive function and for the
presence of moderate-to-severe pain. We regarded
p\ 0.05 as significant. All statistical analyses were con-
ducted with STATA/IC 14 (Stata Corp LP, College Station,
TX, USA).
3 Results
Figure 1 shows the trial profile, wherein each patient is
categorised by the first exclusion criterion that was ful-
filled, after which no further assessments were made.
Table 2 shows group allocation and characteristics of the
162 included patients at baseline. In total, 39 patients
(24.1%) reported adverse events (Table 3), most frequently
in the active buprenorphine group of whom 23 (52%)
withdrew because of adverse events. Thirteen patients
discontinued treatment owing to clinical deterioration or
death; one in the paracetamol group, two who received
placebo tablets, six in the buprenorphine group and four
who received placebo TDS. Between-group differences in
mortality were not statistically significant (Pearson v2 test;
p = 0.447).
From the linear mixed-model analysis (Table 4, Fig. 2),
we found that the placebo group had a significant reduction
in depressive symptoms (CSDD score) of -3.30 (95%
confidence interval -4.68 to -1.92) from baseline to the
13-week follow-up. The active treatment group did not
have a significant CSDD change in the same period [mean
change -0.66 (-2.27 to 0.94)]. The estimated treatment
effect from baseline to 13 weeks was 2.64 (0.55–4.72,
p = 0.013), thus receiving placebo was associated with a
significant reduction in depressive symptoms from baseline
to 13 weeks compared with those who received active
treatment. The observed treatment effects were not affected
by concomitant use of antidepressants or analgesics. Ana-
lysing patients in the different treatment groups separately,
we found that neither active paracetamol nor buprenor-
phine had significant treatment effects on depressive
symptoms from 0 to 13 weeks compared with placebo
(Table 4, Fig. 2). The estimated treatment effects were
1.98 (-0.79 to 4.74, p = 0.162) for paracetamol vs. pla-
cebo tablets, and 3.04 (-0.11 to 6.19, p = 0.059) for
buprenorphine vs. placebo TDS. Grouping patients
according to whether they had moderate-to-severe pain at
baseline did not yield significant treatment effects on
depression compared with placebo; nor did separate anal-
yses for patients with moderate and severe dementia
(Table 4, Fig. 2).
There was no significant reduction in pain in the com-
bined active treatment group (paracetamol and buprenor-
phine) compared with placebo (Table 5, Fig. 3). Active
paracetamol was associated with a significant decrease in
pain from 6- to 13-week assessments compared with pla-
cebo tablets, with an estimated treatment effect of -1.11
(-2.16 to -0.06, p = 0.037). This effect was not observed
for active buprenorphine [coefficient 0.26 (-1.06 to 1.59),
p = 0.697].
4 Discussion
This is the first placebo-controlled study investigating the
efficacy of analgesic treatment for depressive symptoms in
people with moderate-to-severe cognitive impairment and
dementia. We have found that a stepwise increase of
analgesic treatment, using either paracetamol tablets or
buprenorphine TDS, was not effective as a means of
reducing depressive symptoms in these patients. Contrary
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to our initial hypothesis, we found that the placebo group
had a significant decrease in depressive symptoms from
baseline to the 13-week follow-up compared with the
active treatment group. We did not find an overall benefit
of active treatment on pain compared with placebo, but
paracetamol reduced pain significantly from 6 to 13 weeks
compared with placebo tablets (Table 5). Despite this,
depressive symptoms did not decrease in the same group
(Table 4).
While our results appear to indicate the reverse effect: a
significant decrease in depressive symptoms in the placebo
group compared with the active treatment group, this result
must be interpreted with caution for several reasons. This
study includes people with severe dementia, in whom
symptoms of both pain and depression are difficult to
assess. We excluded patients in whom severe pain
(MOBID-2 C 8) was identified because it would be
unethical to risk prolonged untreated pain by randomising
these patients to receive active treatment or placebo, and
recommended instead that the responsible physician should
initiate appropriate analgesic treatment.
Therefore, our results may not be generalisable to
nursing home patients with dementia and severe pain. Most
of the included patients were unable to self-report pain
Fig. 1 Trial profile. Each patient was categorised by the first exclusion criterion that was fulfilled, after which no more assessments were made.
CSDD Cornell Scale for Depression in Dementia, MMSE Mini-Mental State Examination, NHs nursing homes
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reliably because of advanced cognitive impairment.
Although proxy-rated pain is the best available pain
assessment method in this group, we have no method to
ascertain the patients’ subjective pain experience. In
patients with very limited verbal and non-verbal expres-
sion, pain intensity may be underestimated by proxy rating.
Our initial hypothesis was therefore that undiagnosed and
therefore untreated painful symptoms may cause
exacerbated depressive symptoms in people with advanced
dementia.
The CSDD scale has been developed for use in people
with dementia, and has shown good sensitivity and speci-
ficity. However, as noted in a recent systematic review and
meta-analysis, most studies that have tested the scale have
excluded people with severe dementia or communication
deficits, thus limiting the majority of the evidence to people
Table 2 Demographic and
clinical characteristics of
included patients at baseline
Total (n = 162) Placebo (n = 82) Active (n = 80)
Age (y) 85.6 ± 7.4 86.2 ± 6.0 85.0 ± 8.7
Sex (female) 122 (75.3) 63 (76.8) 59 (73.8)
MMSE 7.8 ± 5.8 7.6 ± 5.7 8.0 ± 5.9
MOBID-2 2.7 ± 2.1 3.0 ± 2.3 2.4 ± 1.9
CSDD 11.2 ± 3.7 11.7 ± 4.1 10.8 ± 3.1
NPI-NH total score 32.1 ± 19.8 31.0 ± 20.1 32.8 ± 19.4
NPI-NH depression 4.4 ± 3.8 4.0 ± 3.7 5.0 ± 4.0
Analgesic 81 (50.0) 41 (50.0) 40 (50.0)
Antidepressant 81 (50.0) 50 (61.0) 31 (38.8)
Step 1aa 68 37 31
Step 1bb 5 0 5
Step 2ac 74 38 36
Step 2bd 15 7 8
Numbers represent mean ± standard deviation or number of patients (%)
CSDD Cornell Scale for Depression in Dementia, MMSE Mini-Mental State Examination, MOBID-2
Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale, NPI-NH Neuropsychiatric Inven-
tory-Nursing Home version
aStudy treatment: paracetamol 1 g/placebo tablet three times daily
bStudy treatment: paracetamol 1 g/placebo tablet two times daily ? usual treatment:
paracetamol B 1 g/day
cStudy treatment: buprenorphine 5 lg/h/placebo transdermal system
dStudy treatment: buprenorphine 5 lg/h/placebo transdermal system ? usual treatment: buprenorphine
5 lg/h transdermal system











Patients with adverse reactionsa 4 (10.8%) 2 (5.6%) 8 (17.8%) 25 (56.8%) 39 (24.1%)
Gastrointestinal 0 0 0 7 6
Neurological 0 0 2 12 14
Dermatological 0 0 1 0 1
Psychiatric 0 0 0 17 17
Infection 1 0 0 1 2
Falls/fractures 1 1 1 4 7
Major clinical changes, including
hospitalisation/death
2 1 4 7 14
TDS transdermal system
aEach patient may have had several reported reactions
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with mild-to-moderate dementia [24]. In cognitively intact
populations, the efficacy of pharmaceutical therapies for
both depression and pain is difficult to isolate from
expectation effects, including both placebo and nocebo
effects [27]. Although people with advanced dementia may
have a diminished or absent placebo response [28], the
proxy raters are prone to observer bias such as the Haw-
thorne effect, which could potentially skew the observed
difference between the treatment groups. Furthermore, we
did not assess raters’ expectation of group allocation, a
factor that has been shown to interfere strongly with
observed effects in placebo-controlled trials [27]. As
shown in the first graph of Fig. 2, all patients had a trend
towards decreasing severity of depressive symptoms from
baseline to the 6-week follow-up. Similarly, Fig. 3 shows
that pain tended to decrease from baseline to the 6-week
follow-up, regardless of group allocation. This initial
improvement across all groups exaggerates the apparent
benefit of placebo on depressive symptoms, and may be
caused by observer bias. Similar trends have been shown in
other studies [5, 16].
The high dropout rate observed in the group receiving
active buprenorphine may reduce comparability between
active treatment and placebo conditions, but represents an
important finding as it suggests lower than expected tol-
erability in this population, which warrants further inves-
tigation. In active treatment, only 44 of the 66 planned for
in the final power analysis completed 13-week assess-
ments. This may further limit our ability to detect a positive
effect of treatment compared with placebo. However, our
data are significantly in favour of the placebo condition
(p = 0.013), probably because the obtained mean CSDD
difference of 2.64 at 13 weeks was larger than the thresh-
old for a clinically relevant difference of 2.0 (standardized
effect size 0.4) used in the power analysis. This means that
the sample size was sufficient to explore our primary aim,
and may indicate that adverse effects of active treatment
led to apparent worsening of depressive symptoms. Known
adverse effects of buprenorphine include symptoms such as
sedation, reduced appetite and anxiety, which may overlap
with items assessed by the CSDD scale and possibly be
interpreted as increased depression. Secondary analyses, in
Table 4 Estimated effect of active analgesic treatment on primary outcome (Cornell Scale for Depression in Dementia depressive symptoms)
compared with placebo; mixed-model analysis including exploratory subgroup analyses
N From baseline to 13 wk From baseline to 6 wk From 6 to 13 wk
C (95% CI) P value C (95% CI) P value C (95% CI) P value
Primary analysis
All patients 160 2.64 (0.55–4.72) 0.013 0.74 (- 1.03 to
2.52)




MMSE 11–20 49 2.24 (- 1.24 to
5.72)
0.207 0.33 (- 2.50 to
3.16)
0.818 1.91 (- 2.05 to
5.86)
0.344
MMSE 0–10 92 1.10 (- 1.49 to
3.69)
0.405 0.56 (- 1.75 to
2.86)
0.635 0.54 (- 2.27 to
3.35)
0.705
Stratified on drug type
Paracetamol/placebo tablets 73 1.98 (- 0.79 to
4.74)
0.162 0.40 (- 2.39 to
3.18)
0.780 1.58 (- 1.49 to
4.64)
0.313
Buprenorphine/placebo TDS 89 3.04 (- 0.11 to
6.19)
0.059 0.96 (- 1.45 to
3.37)
0.433 2.07 (- 1.06 to
5.20)
0.194
Stratified on pain level
MOBID-2\ 3 57 2.65 (- 0.49 to
5.80)
0.098 1.42 (- 1.00 to
3.83)
0.251 1.24 (- 1.40 to
3.87)
0.357
MOBID-2 C 3 103 2.25 (- 0.55 to
5.04)
0.115 0.47 (- 1.98 to
2.91)
0.709 1.78 (- 1.31 to
4.88)
0.260
MOBID-2 C 3 and
paracetamol
47 1.63 (- 2.68 to
5.94)
0.459 - 0.38 (- 4.51 to
3.76)
0.858 2.01 (- 2.52 to
6.53)
0.385
MOBID-2 C 3 and
buprenorphine
61 2.19 (- 1.35 to
5.73)
0.226 1.32 (- 1.87 to
4.51)
0.418 0.87 (- 2.84 to
4.58)
0.646
C coefficient for time 9 treatment interaction, CI confidence interval, MMSE Mini-Mental State Examination, MOBID-2 Mobilisation-Obser-
vation-Behaviour-Intensity-Dementia-2 Pain Scale, N number of patients with at least one valid assessment, TDS transdermal system. See also
the Electronic Supplementary Material 2, which reports all corresponding coefficients for change
552 A. Erdal et al.
which patients were grouped based on the presence of
moderate-to-severe pain, cognitive status and choice of
analgesic treatment all show a similar trend in favour of the
placebo condition, although these associations did not
reach significance, probably because the sample size did
not provide sufficient power for subgroup analyses.
An important limitation to the interpretation of our
results is therefore that we do not have a sufficient sample
size to determine whether there was a significant differ-
ential effect between paracetamol and buprenorphine on
depressive symptoms. Furthermore, the extensive list of
exclusion criteria was necessary to include this frail pop-
ulation in the current trial, but also limits the generalis-
ability of our results to a more heterogeneous group of
nursing home patients. A recent study found that patients
with depression were more likely to be prescribed anal-
gesic treatments [29]. This means that an unknown pro-
portion of patients who theoretically may have benefited
from the intervention were excluded from our study: 562
patients (38% of the 2323 patients screened) were excluded
because of opioid analgesic use, without any further
assessments of eligibility. This choice was made inten-
tionally to assess treatment effects in patients who were not
already using high doses of the study drugs, and in whom
untreated pain was not identified as a primary clinical
issue.
Several previous studies have suggested that depression
in nursing home patients with cognitive impairment may be
related to untreated pain. The association between pain and
depression, also known as the pain-depression dyad, has
been observed in nursing home patients at all stages of
cognitive impairment [13, 14]. Secondary analyses from a
previous cluster-randomised study, which assessed the
efficacy of a stepwise increase in analgesic treatment for
depressive symptoms in 175 nursing home patients with
dementia and agitation, found a significant but small ben-
efit on the mood syndrome cluster assessed with the Neu-
ropsychiatric Inventory – Nursing Home version [16].
They included patients with agitation, whereas in our study
depression was an inclusion criterion. Furthermore, a
higher proportion of patients were allocated to receive
paracetamol relative to our study [120 (69%) and 36 (45%),
respectively]. They had an open-label design with the
control group receiving usual care, consequently their
results may have been biased owing to a Hawthorne effect.
These methodological differences may in part explain our
apparently opposing result.
Nonetheless, our rigorous placebo-controlled design
justifies our conclusion that analgesic treatment alone is not
sufficient to improve depressive symptoms in nursing home
patients with dementia and depression in the absence of
severe pain. By excluding patients with severe pain from
the trial, we may have limited the potential to find
beneficial effects of analgesic treatment for depression.
However, subgroup analyses stratified on pain level did not
indicate that patients with moderate-to-severe pain had a
more beneficial effect of active treatment on depressive
symptoms. Although the group that received active
paracetamol had a significant decrease in pain compared
with those who received placebo tablets, there was a trend
towards more persistent depressive symptoms in this group
during the same period. While the latter result was not
statistically significant, it indicates that the negative result
on the main outcome of the current trial cannot be
explained by the absence of pain at baseline.
Importantly, no clear causal relationship between pain
and increased depression, or between depression and
increased pain, has been established. Pain and depression
are known to mutually exacerbate each other, a relationship
that may be most accurately characterised as multifactorial.
Although many nursing home patients with depression
have comorbid chronic pain, other associated problems
such as isolation and lack of social contact or meaningful
activity may be equally important [30]. In this perspective,
it may not be surprising that an isolated pain intervention is
insufficient to improve depressive symptoms. Rather, our
results show that careful assessment of painful symptoms,
followed by the implementation and continuous re-evalu-
ation of appropriate interventions, is an absolute require-
ment for adequate care in this population, as both untreated
pain and use of unnecessary analgesics may lead to harm.
Patients with cognitive impairment are particularly sus-
ceptible to the adverse effects of analgesics and antide-
pressants, and may be unable to communicate verbally the
severity of their symptoms. This makes it particularly
challenging to ensure that the benefit of pharmacological
treatment outweighs any potential harm.
A 2011 study found that physicians in Norwegian
nursing homes rarely diagnosed depression before pre-
scribing antidepressants, and that treatment with antide-
pressants often was continued despite great uncertainty of
their effectiveness [31]. Forty percent of nursing home
patients in Norway use antidepressants [32]. This is in line
with the pooled percentage of antidepressant use in Wes-
tern European nursing homes [1], and indicates that the
need for improved prescribing practice is not exclusive to
Norway. Future advances should go towards more com-
prehensive treatment strategies that include both pharma-
cological and non-pharmacological interventions, as
exemplified by Chen and Lin [33]. Non-pharmacological
interventions that have been shown to reduce depressive
symptoms in dementia include caregiver education and
engagement in physical activity and pleasant events, but
more evidence is needed to determine which strategies are
most effective [34, 35].
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Buprenorphine elicits its pharmacological effects on the
opioidergic system, but has previously been suggested as a
potential agent for treatment-resistant depression as some
patients have had promising results [18]. However, based
on the high rate of adverse events and absence of benefit on
depressive symptoms, it is unlikely that buprenorphine has
any potential as a treatment for depression in nursing home
patients with dementia. The efficacy and tolerability of
buprenorphine TDS have not previously been investigated
in people with dementia in a placebo-controlled study.
Buprenorphine has similar pharmacokinetic properties and
does not require dose adjustment in the elderly compared
with younger patients [36]. In a study comparing healthy
elderly people aged C 75 years to those aged 50–60 years,
buprenorphine TDS was found to have a slightly lower
steady-state concentration with higher variability in the
elderly group [37]. The same study found a lower rate of
adverse events in the elderly subjects compared with the
younger controls [37].
In the current study, the dropout rate owing to adverse
events of buprenorphine exceeded that reported in a pre-
vious study of buprenorphine in patients with dementia
[16], and is more than twice that reported in a study of
opioid-naı̈ve, cognitively intact elderly patients (aged
C 75 years), which found that 21% dropped out because of
adverse events of buprenorphine [38]. This suggests that
people with dementia may be more susceptible to adverse
events of buprenorphine compared with elderly patients
without cognitive impairment.
Because few large-scale safety studies of opioid anal-
gesics in elderly patients exist, and none have included
people with advanced dementia, we do not know whether
this may represent a class effect of opioid analgesics or
whether buprenorphine may be more poorly tolerated in
frail elderly people and people with dementia compared
with other opioid analgesics. In light of the widespread use
of buprenorphine TDS and other opioid analgesics in
nursing home patients, particularly in the oldest patients
[39, 40], there is an urgent need for high-powered studies
investigating the safety and efficacy of buprenorphine and
other opioid analgesics for treating pain in people with
advanced dementia.
bFig. 2 Change in depressive symptoms (Cornell Scale for Depression
in Dementia) throughout the study period. CI confidence interval,
MMSE Mini-Mental State Examination, MOBID-2 Mobilisation-
Observation-Behaviour-Intensity-Dementia-2 Pain Scale
Table 5 Estimated effect of active analgesic treatment on secondary outcome [Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain
Scale (MOBID-2) pain intensity] compared with placebo; mixed-model analysis including exploratory subgroup analyses
N From baseline to 13 wk From baseline to 6 wk From 6 to 13 wk
C (95% CI) P value C (95% CI) P value C (95% CI) P value
Secondary analysis
All patients 147 - 0.19 (- 1.02 to
0.64)
0.652 0.19 (- 0.59 to
0.97)




MMSE 11–20 44 - 1.01 (- 2.44 to
0.41)
0.162 0.39 (- 0.94 to
1.73)
0.563 - 1.41 (- 2.83 to
0.01)
0.051
MMSE 0–10 87 0.12 (- 1.02 to
1.26)
0.838 0.03 (- 1.05 to
1.11)
0.960 0.09 (- 1.13 to
1.32)
0.884
Stratified on drug type
Paracetamol/placebo tablets 69 - 0.98 (- 2.00 to
0.05)
0.061 0.14 (- 0.83 to
1.10)
0.779 - 1.11 (- 2.16 to
-0.06)
0.037
Buprenorphine/placebo TDS 78 0.47 (- 0.77 to
1.71)
0.456 0.21 (- 0.98 to
1.39)
0.733 0.26 (- 1.06 to
1.59)
0.697
Stratified on pain level
MOBID-2 C 3 90 - 0.57 (- 1.77 to
0.62)
0.347 -0.16 (- 1.24 to
0.93)
0.779 - 0.42 (- 1.63 to
0.79)
0.498
MOBID-2 C 3 and
paracetamol
38 - 1.36 (- 3.27 to
0.55)
0.164 0.07 (- 1.67 to
1.82)
0.933 - 1.43 (- 3.25 to
0.39)
0.123
MOBID-2 C 3 and
buprenorphine
52 0.23 (- 1.32 to
1.77)
0.775 -0.38 (- 1.81 to
1.05)
0.607 0.60 (- 1.04 to
2.25)
0.474
C coefficient for time 9 treatment interaction, CI confidence interval, CSDD Cornell Scale for Depression in Dementia, MMSE Mini-Mental
State Examination, N number of patients with at least one valid assessment, TDS transdermal system. See also the Electronic Supplementary
Material 3, which reports all corresponding coefficients for change
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5 Conclusion
Analgesic treatment did not reduce depression in patients
with cognitive impairment and depressive symptoms.
Patients who received active treatment had more persistent
depressive symptoms than those who received placebo,
possibly owing to adverse effects. These results point to
the importance of continuous symptom assessment when
caring for people with dementia, ensuring that analgesics
are given based on the correct indications with a minimal
risk of harm, and using both pharmacological and non-
pharmacological interventions as appropriate. Active
buprenorphine was associated with high rates of adverse
events, and should be prescribed cautiously in people with
dementia.
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understand the purpose and implications of study participation. We
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give consent would not affect the quality of the medical care provided
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